CA2001643A1 - Solution multi-dose de vincristine sans agent de conservation - Google Patents
Solution multi-dose de vincristine sans agent de conservationInfo
- Publication number
- CA2001643A1 CA2001643A1 CA 2001643 CA2001643A CA2001643A1 CA 2001643 A1 CA2001643 A1 CA 2001643A1 CA 2001643 CA2001643 CA 2001643 CA 2001643 A CA2001643 A CA 2001643A CA 2001643 A1 CA2001643 A1 CA 2001643A1
- Authority
- CA
- Canada
- Prior art keywords
- solution
- vincristine
- salt
- product
- product according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 title claims abstract description 49
- 229960004528 vincristine Drugs 0.000 title claims abstract description 35
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 title claims abstract description 34
- 150000003839 salts Chemical class 0.000 claims abstract description 14
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 7
- 229940127557 pharmaceutical product Drugs 0.000 claims abstract description 7
- 239000000243 solution Substances 0.000 claims description 53
- 238000000034 method Methods 0.000 claims description 15
- 235000000346 sugar Nutrition 0.000 claims description 10
- 150000008163 sugars Chemical class 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 150000003467 sulfuric acid derivatives Chemical class 0.000 claims description 6
- 239000006174 pH buffer Substances 0.000 claims 5
- 150000001298 alcohols Chemical class 0.000 claims 2
- 239000007974 sodium acetate buffer Substances 0.000 claims 2
- BHZOKUMUHVTPBX-UHFFFAOYSA-M sodium acetic acid acetate Chemical compound [Na+].CC(O)=O.CC([O-])=O BHZOKUMUHVTPBX-UHFFFAOYSA-M 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 abstract description 3
- 239000012266 salt solution Substances 0.000 description 15
- 239000003755 preservative agent Substances 0.000 description 12
- 238000012360 testing method Methods 0.000 description 10
- AQTQHPDCURKLKT-JKDPCDLQSA-N vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-JKDPCDLQSA-N 0.000 description 9
- 238000009472 formulation Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 229960002110 vincristine sulfate Drugs 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 230000000845 anti-microbial effect Effects 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 238000011109 contamination Methods 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 230000002939 deleterious effect Effects 0.000 description 3
- 239000007972 injectable composition Substances 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000002906 microbiologic effect Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 241000427202 Adria Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 208000005045 Interdigitating dendritic cell sarcoma Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 241000863480 Vinca Species 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- -1 lactose or mannitol Chemical class 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 208000025036 lymphosarcoma Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000031864 metaphase Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229960003552 other antineoplastic agent in atc Drugs 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 description 1
- 229940028393 vincasar Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28884488A | 1988-12-23 | 1988-12-23 | |
| US288,844 | 1988-12-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2001643A1 true CA2001643A1 (fr) | 1990-06-23 |
Family
ID=23108904
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA 2001643 Abandoned CA2001643A1 (fr) | 1988-12-23 | 1989-10-27 | Solution multi-dose de vincristine sans agent de conservation |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2001643A1 (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004314154B2 (en) * | 2003-12-23 | 2011-03-24 | Pierre Fabre Medicament | Pharmaceutical composition of vinflunine which is intended for parenteral administration preparation method thereof and use of same |
-
1989
- 1989-10-27 CA CA 2001643 patent/CA2001643A1/fr not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004314154B2 (en) * | 2003-12-23 | 2011-03-24 | Pierre Fabre Medicament | Pharmaceutical composition of vinflunine which is intended for parenteral administration preparation method thereof and use of same |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0650729B1 (fr) | Formulations de rapamycine pour l'injection intraveineuse | |
| AU768169B2 (en) | Pharmaceutically stable oxaliplatinum preparation for parenteral administration | |
| EP2656848B1 (fr) | Solution de gemcitabine prête à être infusée | |
| JPS6191131A (ja) | 医薬品の吸着防止方法および組成物 | |
| EP3811927B1 (fr) | Forme posologique parentérale stable d'acétate de cétrorélix | |
| US20060154891A1 (en) | Ready-to-use gemcitabine solutions and gemcitabin concentrates | |
| SE466383C (sv) | Injicerbar bruksfärdig antracyklinglykosidlösning samt förfarande för dess framställning | |
| US4619935A (en) | Stable oncolytic formulations | |
| KR20020031388A (ko) | 성장 호르몬 제제 | |
| EP3554474B1 (fr) | Compositions de micafungine | |
| KR101166347B1 (ko) | 비경구적 투여용 빈플루닌 약학적 조성물, 제조방법 및이의 용도 | |
| EP2887953B1 (fr) | Formulation injectable améliorée de daptomycine | |
| EP0299527B1 (fr) | Solutions aqueuses de chlorhydrate de doxorubicine | |
| CA2001643A1 (fr) | Solution multi-dose de vincristine sans agent de conservation | |
| IE55388B1 (en) | Stable pharmaceutical solutions of vinca alkaloids | |
| JPS63215633A (ja) | アントラサイクリングリコシド溶液およびその製造方法 | |
| EP3054924B1 (fr) | Formulations pharmaceutiques stables de caspofungine | |
| US7070796B1 (en) | Pharmaceutically stable oxaliplatinum preparation for parenteral administration | |
| JPS5929617A (ja) | ビンカ・アルカロイド製剤 | |
| EP3943068A1 (fr) | Composition de suxaméthonium et seringue préremplie correspondant | |
| DE3907079A1 (de) | Ifosfamid-mesna-lyophilisat und verfahren zu dessen herstellung | |
| WO2023214433A1 (fr) | Compositions parentérales stables de parécoxib | |
| EP4226926A1 (fr) | Formulation pharmaceutique stable prête à diluer comprenant du cyclophosphamide | |
| HK40049906A (en) | A stable parenteral dosage form of cetrorelix acetate | |
| HK40049906B (en) | A stable parenteral dosage form of cetrorelix acetate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |